

ASX RELEASE

**Volpara signs major contract with leading US outpatient diagnostic imaging provider;
largest contract signed to date**

Highlights:

- **Five-year, US\$2.15M contract representing US\$430K Annual Recurring Revenue (ARR)**
- **Under the agreement, Volpara® Patient Hub™ will replace multiple legacy patient tracking systems**
- **Agreement also includes Volpara® Risk™ and Scorecard™, underscoring the value of the Volpara® Breast Health Platform™**

Wellington, NZ, 5 October 2021: Volpara Health Technologies Limited ("Volpara," "the Group," or "the Company"; ASX:VHT), a global health technology software leader providing an integrated platform for the delivery of personalised breast care, has entered into its highest-value contract to date through a five-year, US\$2.15M contract with a leading US outpatient diagnostic imaging provider, representing US\$430K ARR.

Volpara will install its Patient Hub software across the customer's extensive network of imaging centres located in 11 states to provide a standardised patient tracking platform that incorporates Volpara Risk and Scorecard—the most clinically validated density software available today. This will enable the customer to accurately triage each patient into the appropriate personalised breast cancer screening pathway.

Dr Ralph Highnam, Group CEO of Volpara, said: "While we would not normally announce individual deals, this is Volpara's highest-value contract signed to date. We are experiencing tremendous momentum for our platform in the market as we bring together best-of-breed patient tracking, risk assessment, and density scoring to allow our customers to provide their patients with the individualised care they deserve. Our platform provides both Volpara and our customers with a significant advantage and is enabling us to seek out opportunities that did not exist even a couple of years ago."

Authorisation & Additional Information

This announcement was authorised by the Board of Volpara Health technologies Limited.

ENDS

For further information, please contact:

Ralph Highnam, CEO

Volpara Health Technologies

ralph.highnam@volparahealth.com

t: +64 21 149 0541

Trevor Chappell

WE Communications

WE-AUVolpara@we-worldwide.com

t: +61 407 933 437

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$132 million, including A\$37 million in April/May 2020, and has made two significant acquisitions in MRS Systems, Inc. (patient tracking software), and CRA Health, LLC (risk and genetics software). VHT is based in Wellington, New Zealand.

For more information, visit www.volparahealth.com.